Premium
18F‐2‐deoxy‐2‐fluoro‐D‐glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron‐emission tomography
Author(s) -
Wahl Richard L.,
Hutchins Gary D.,
Buchsbaum Donald J.,
Liebert Monica,
Grossman H. Barton,
Fisher Susan
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910315)67:6<1544::aid-cncr2820670614>3.0.co;2-0
Subject(s) - medicine , positron emission tomography , melanoma , renal cell carcinoma , nuclear medicine , cancer , adenocarcinoma , ovarian cancer , pathology , carcinoma , cancer research
The positron‐emitting glucose analogue 18 F‐2‐fluoro‐2‐deoxy‐d‐glucose (FDG) was evaluated for its accretion into the following subcutaneous human tumor xenografts in nude mice: B‐cell lymphoma (Namalwa or Raji), ovarian carcinoma (HTB77), colon cancer (SW948), choriocarcinoma (BEWO), bladder cancer (UM‐UC‐2), renal cell carcinoma (UM‐RC‐3), neuroblastoma (Mey), melanoma (HTB63), and small cell lung carcinoma (NCI69). Two hours postinjection, tumor uptakes ranged from 0.027 (colon cancer) to 0.125% kg injected dose/g (melanoma); and was greater than 0.085 in the Namalwa lymphomas and the renal cell carcinomas. Tumor‐blood ratios of up to 23:1 were seen 2 hours postinjection (melanoma) with a mean tumor‐blood ratio for all tumors of 12.3 ± 1.8. Uptake in the other tumors was intermediate. When evaluated, tumor uptake was slightly greater at 1 than at 2 hours postinjection, although target‐background ratios were generally higher at 2 hours postinjection. This compound, FDG, may have broad applicability as a tracer for positron‐emission tomographic imaging of many human malignancies.